.gif)
Osteoarthritis
Injection of triamcinolone versus saline in patients with knee osteoarthritis
Rheumatol Rehabil. 1980 Nov;19(4):212-716 patients (24 knees) with knee osteoarthritis were randomized to an injection with either 20mg triamcinolone hexacetonide or placebo. After 1 week, patients initially administered a triamcinolone hexacetonide injection received a saline injection, and patients initially administered a saline injection received a triamcinolone hexacetonide injection. Patients were assessed for pain and tenderness & stiffness before each injection, and at 1 week after the second injection. At 1 week after the first injection, patients who received a triamcinolone hexacetonide injection demonstrated a significant within-group reduction in pain and tenderness, while patients who received placebo did not. At 1 week after the second injection, patients who initially received the triamcinolone hexacetonide injection demonstrated no significant further reduction in pain and tenderness following saline injection, while those who initially received a saline injection demonstrated a significant within-group reduction in pain and tenderness following the second injection with triamcinolone hexacetonide.
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now

Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.